Home › Companies › ANNX

Annexon, Inc.

ANNX Rare disease Lead: NDA Submitted 3 Biotech Distilled articles ↓

Hematology Neurology Ophthalmology Renal Protein Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (6 active programs)

tanruprubart

Protein Target: C1q

vonaprument

Protein Target: C1q

Geographic Atrophy Phase 3 intravitreal

ANX1502

Small Molecule Target: C1s

Cold Agglutinin Disease Phase 2 oral

ANX009

Protein Target: C1q

Lupus Nephritis Phase 1 subcutaneous

Biotech Distilled coverage (3)

2026-05-08 UPDATE: Annexon (ANNX) - The Dilution Gun Has Fired 🔒 Paid
2026-04-04 UPDATE: Annexon (ANNX) - Spring Cleaning, Shelf Registrations, and the Dilution Gap 🔒 Paid
2026-02-27 Annexon (ANNX): Scientific Deep Dive for ANX007 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.